Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
Therapeutic options for treating advanced melanoma are progressing rapidly. Although anti-programmed cell death 1 (PD1) antibodies (e.g., nivolumab, pembrolizumab) have been approved as first-line and anchor drugs, respectively, for treating advanced melanoma, the efficacy appears limited as we expe...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2019-07-01
|
| Edice: | Frontiers in Medicine |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/article/10.3389/fmed.2019.00174/full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|